Compare Humana Inc (HUM) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Xpeng Inc - ADR — how do they compare? Humana Inc trades at $453 (market cap $46.49B), while Xpeng Inc - ADR trades at $9.81 (market cap $9.16B). The key difference: Humana Inc is far larger — about 5.1× Xpeng Inc - ADR's market cap, and Humana Inc pays a 0.91% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Xpeng Inc - ADR for 80 Days on average.
| HUM | XPEV | |
|---|---|---|
Market Cap | $46.49B | $9.16B |
Volume | 2,567,704 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $409.85 | $28.07 |
52-Week Low | $163.67 | $9.25 |
Typical Hold Time | 53 Days | 80 Days |
Enterprise Value | $53.84B | $11.09B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $441.74, up 11.41% over 24 hours, reflecting strong momentum. The stock shows bullish technical signals with support at $391 and resistance at $406. Fundamentally, revenue grew to $129.66B in 2025, though net income margin compressed to 0.88%. Recent news highlights a Barclays upgrade to a $515 price target and upcoming Q3 earnings on November 6, 2026.
The outlook is cautiously optimistic with a consensus price target of $457.05 implying modest upside. Risks include margin pressure from Medicare Advantage plan changes and potential regulatory scrutiny. Institutional activity is mixed, with Bank of America adding a position while some funds reduced stakes.
XPeng (XPEV) trades at $9.58, up 0.21% today, with a bearish technical signal despite oversold RSI readings. The company reported strong Q4 2025 earnings beat but missed Q1 and Q2 2026 expectations. Revenue grew to $76.72B in 2025, with net losses narrowing to -$1.14B. Recent news highlights XPeng's expansion into humanoid robotics and global vehicle launches, including the G9L SUV debut at the Paris Motor Show.
XPeng shows improving revenue growth and narrowing losses, but persistent unprofitability and high EV/EBITDA of 144.25 pose valuation concerns. Analyst consensus is bullish with a $17.55 price target, though execution risks in new robotics ventures and competitive EV market pressures remain key challenges for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
